Abstract
PURPOSE: Quantify the impact of additional imaging doses on clinical dose constraints during lung stereotactic body radiotherapy (SBRT) treatment utilizing stereoscopic/monoscopic real-time tumor monitoring. MATERIALS AND METHODS: Thirty lung SBRT patients treated with the volumetric arc therapy technique were randomly selected from the institutional clinical database. Contours of patients' and computed tomography data were extracted from the Eclipse treatment planning system, along with information regarding the treatment dose. Subsequently, patient-specific three-dimensional real-time imaging dose distributions were computed using a validated Monte Carlo simulation of the ExacTrac imaging. The 3D imaging dose was added to the treatment dose, and the influence of the imaging dose on clinical dose constraints was analyzed for planning target volume (PTV) and various organs at risk (OARs). RESULTS: Among the 30 patients, 14 patients exhibited one or more failed OAR constraints based solely on the treatment dose, resulting in a total of 24 constraint failures. The addition of the real-time imaging dose altered the pass/fail criteria for one OAR constraint and two PTV constraints. The change in constraint due to additional imaging dose relative to the prescription dose was less than 1% for all patients, except for one case, where it reached 1.9%, which had remained below the threshold of 5% recommended by AAPM TG-180 guidelines. Furthermore, the additional imaging dose relative to the treatment dose resulted in an increase in OAR constraints ranging from 0 to 27% (mean of 0.8%), with nine cases exceeding 5%. CONCLUSION: The current study represents the first attempt to investigate the impact of additional imaging doses on clinical planning constraints in real-time tumor monitoring during lung SBRT utilizing ExacTrac imaging system. The addition of an imaging dose will likely have minimal clinical impact.